25 mg/ml (100 mg/4 ml or 14 mg/16 ml) concentrate for solution for infusion

  • Antineoplastic agents. Monoclonal antibodies.
  • Bevacizumab is a recombinant humanized monoclonal antibody. Bevacizumab binds to vascular endothelial growth factor (VEGF) and thereby inhibits the binding of VEGF to its receptors, Flt-1 (VEGFR-1) and KDR (VEGFR-2), on the surface of endothelial cells. As a result, it blocks angiogenesis, thereby inhibiting tumour growth.
  • B-MAB is approved to treat metastatic colorectal cancer, metastatic HER2-negative breast cancer, certain lung cancer, metastatic kidney cancer, ovarian and cervical cancers.
  • B-MAB is the first biosimilar of Avastin® in Belarus with the identity efficacy and safety profile proven in comparative clinical studies.